A Phase 3, Intergroup Multicentre, Randomized, Controlled 3 Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide in Combination With Dexamethasone (RD) Versus Melphalan, Prednisone and Lenalidomide (MPR) Versus Cyclophosphamide, Prednisone and Lenalidomide (CPR) in Newly Diagnosed Elderly Multiple Myeloma Subjects.

Trial Profile

A Phase 3, Intergroup Multicentre, Randomized, Controlled 3 Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide in Combination With Dexamethasone (RD) Versus Melphalan, Prednisone and Lenalidomide (MPR) Versus Cyclophosphamide, Prednisone and Lenalidomide (CPR) in Newly Diagnosed Elderly Multiple Myeloma Subjects.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2018

At a glance

  • Drugs Lenalidomide (Primary) ; Cyclophosphamide; Dexamethasone; Melphalan; Prednisone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Jun 2018 Results of a subgroup analysis evaluating the impact of patient frailty status on outcome of different lenalidomide-containing regimes presented at the 23rd Congress of the European Haematology Association
    • 12 Dec 2017 Results of a subanalysis from Gimema-MM-03-05 and EMN01 studies, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 12 Dec 2017 Updated results will be presented at the meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top